Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer.
Aged
Aged, 80 and over
Bacterial Vaccines
/ therapeutic use
Biomarkers, Tumor
/ blood
Cancer Vaccines
/ therapeutic use
Female
Flow Cytometry
/ methods
GPI-Linked Proteins
/ immunology
Humans
Immunotherapy
/ methods
Leukocytes, Mononuclear
/ drug effects
Listeria monocytogenes
/ immunology
Male
Mass Spectrometry
/ methods
Mesothelin
Middle Aged
Neoplasm Metastasis
Pancreatic Neoplasms
/ drug therapy
Prospective Studies
Retrospective Studies
Single-Cell Analysis
Survival Rate
Treatment Outcome
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
09
2019
revised:
27
11
2019
accepted:
28
02
2020
pubmed:
7
3
2020
medline:
5
1
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
The identification of biomarkers for patient stratification is fundamental to precision medicine efforts in oncology. Here, we identified two baseline, circulating immune cell subsets associated with overall survival in patients with metastatic pancreatic cancer who were enrolled in two phase II randomized studies of GVAX pancreas and CRS-207 immunotherapy. Single-cell mass cytometry was used to simultaneously measure 38 cell surface or intracellular markers in peripheral blood mononuclear cells obtained from a phase IIa patient subcohort (
Identifiants
pubmed: 32132105
pii: 2326-6066.CIR-19-0650
doi: 10.1158/2326-6066.CIR-19-0650
pmc: PMC7832081
mid: NIHMS1606751
doi:
Substances chimiques
Bacterial Vaccines
0
Biomarkers, Tumor
0
Cancer Vaccines
0
GPI-Linked Proteins
0
GVAX vaccine
0
Mesothelin
J27WDC343N
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-617Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210171
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7
pubmed: 15365184
Immunology. 2011 Sep;134(1):17-32
pubmed: 21711350
Immunol Lett. 2009 Dec 2;127(1):27-32
pubmed: 19715728
J Immunol. 2015 Aug 1;195(3):773-9
pubmed: 26188071
BMC Immunol. 2001;2:10
pubmed: 11696237
Gut. 2014 Nov;63(11):1690-1
pubmed: 24633728
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Clin Vaccine Immunol. 2009 Nov;16(11):1648-53
pubmed: 19726615
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
J Clin Oncol. 2015 Apr 20;33(12):1325-33
pubmed: 25584002
Clin Cancer Res. 2008 Mar 1;14(5):1455-63
pubmed: 18316569
Front Biosci (Landmark Ed). 2009 Jan 01;14:3771-81
pubmed: 19273309
J Immunol. 1998 Apr 1;160(7):3096-100
pubmed: 9531263
Sci Transl Med. 2014 Sep 24;6(255):255ra131
pubmed: 25253674
PLoS One. 2014 Feb 03;9(2):e87705
pubmed: 24498358
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Clin Cancer Res. 2012 Feb 1;18(3):858-68
pubmed: 22147941
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
J Leukoc Biol. 2010 Jan;87(1):107-16
pubmed: 19880576
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
J Exp Med. 2004 Aug 2;200(3):297-306
pubmed: 15289501
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
J Immunol. 2005 Jun 1;174(11):6757-63
pubmed: 15905516
J Exp Med. 1997 Nov 3;186(9):1407-18
pubmed: 9348298
J Immunol. 2014 Feb 1;192(3):840-4
pubmed: 24443506